Companies

Pfizer, Tris Pharma Reach $41.5 Million Settlement With Texas Over ADHD Drug

Texas sued the companies in 2023, alleging they provided adulterated Quillivant XR to children on Medicaid despite manufacturing and quality control issues.
0
Pfizer, Tris Pharma Reach $41.5 Million Settlement With Texas Over ADHD Drug
The Pfizer logo on its headquarters building in the Manhattan borough of New York City, in this file photo. Carlo Allegri/Reuters/File Photo
|Updated:

Texas Attorney General Ken Paxton on Nov. 19 announced that his office had reached a $41.5 million settlement with Pfizer and Tris Pharma to resolve a November 2023 lawsuit regarding the companies’ distribution of the attention deficit/hyperactivity disorder (ADHD) medication Quillivant to children.

Paxton sued the pharmaceutical companies and Tris Pharma CEO Ketan Mehta, alleging that they knowingly provided adulterated Quillivant XR to Texas children on Medicaid despite flawed manufacturing practices that led to multiple quality-control failures.
Rob Sabo
Rob Sabo
Author
Rob Sabo has worked as a business journalist for nearly two decades and covers a broad range of business topics for The Epoch Times.